Navigation Links
PDL BioPharma Announces Fourth Quarter and Full Year 2012 Financial Results
Date:3/1/2013

#160; Data from this trial will be submitted to European regulatory authorities and to the U.S. Food and Drug Administration (FDA) for potential approval.

2013 Dividends On January 30, 2013, PDL's Board of Directors declared regular quarterly dividends of $0.15 per share of common stock, payable on March 12, June 12, September 12 and December 12 of 2013 to all stockholders who own shares of PDL on March 5, June 5, September 5 and December 5 of 2013, the record dates for each of the dividend payments, respectively.

Revenue Guidance for 2013As previously announced, PDL will continue to provide revenue guidance for each quarter in the third month of that quarter. First quarter 2013 revenue guidance will be provided in early March.

Conference Call DetailsPDL will hold a conference call to discuss financial results at 4:30 p.m. ET today, March 1, 2013.

To access the live conference call via phone, please dial (800) 668-4132 from the United States and Canada or (224) 357-2196 internationally. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through March 8, 2013, and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 12523654.

To access the live and subsequently archived webcast of the conference call, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new inc
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
2. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
4. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
5. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
7. S1 Biopharma Expands Focus to Include Male Sexual Health
8. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
9. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
10. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
11. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 ... plc (NASDAQ: ENDP ) (TSX: ENL), and ... announced today that they have submitted a New Drug ... U.S. Food and Drug Administration (FDA).  Buprenorphine HCl Buccal ... severe enough to require daily, around-the-clock, long-term opioid treatment ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has ... Glucose Market" report to their offering. ... insight focuses on the developments in the self-monitoring blood ... . Reimbursement analysis and the effects of competitive bidding ... 73 SMBG meters have been performed, based on the ...
(Date:12/22/2014)... and STOCKHOLM , Dec. ... (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that ... of the European Medicines Agency (EMA) has adopted a ... histolyticum) for the treatment of adult men with Peyronie,s ... at least 30 degrees at the start of therapy. ...
Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... 2007 /PRNewswire/ -- Mersana, a,cancer therapeutics company, announced ... product candidate, XMT-1001, will,be presented in two posters ... of Cancer Research (AACR) taking place April,14-18th in ... can be,viewed online at the AACR website at ...
... 13, 2007 - Biogen Idec Inc.,(NASDAQ: BIIB) ... the,Academy of Managed Care Pharmacy's (AMCP) 2007 ... a cost-effective therapy in,multiple sclerosis (MS) when ... comprehensive analysis of medical and pharmacy,costs, the ...
Cached Medicine Technology:Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001,at American Association of Cancer Research Annual Meeting 2New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective,Relative to Other Interferon Therapies for Multiple Sclerosis 2New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective,Relative to Other Interferon Therapies for Multiple Sclerosis 3
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
(Date:12/25/2014)... December 25, 2014 The short film “Color ... created in honor of a true 9/11 hero, Welles Remy ... festivals including the 24 hours of Nuremberg International Short Film ... , Actress, screenwriter and director Luciana Lagana ... film together with her husband, Gregory Graham - ...
(Date:12/25/2014)... Woodland Hills, California (PRWEB) December 25, 2014 ... in her home in Woodland Hills, California after an ... Harris passed away on Christmas Eve evening in her ... battle with aggressive metastatic breast cancer. ... International for over forty years, she pioneered and championed ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... illnesses can receive effective, less expensive care from a clinic ... a team of dedicated health care professionals, a new study ... and need either hospitalization or a trip to the emergency ... clinic at the University of Texas in Houston versus usual ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Among early stage breast cancer ... half of one percent will eventually develop leukemia as ... The finding comes from a review of more ... 2007, and it suggests that the risk for developing ... had previously thought. "The frequency of bone marrow ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... , SOUTH SAN FRANCISCO, Calif., July 10 ... the International Society on Thrombosis and Haemostasis (ISTH) XII ... drug elinogrel, a P2Y(12) ADP receptor antagonist currently in ... inhibitor anticoagulant antidote in pre-clinical development, as well as ...
... adulthood, study shows , THURSDAY, July 9 (HealthDay News) ... can persist into adulthood, U.S. researchers report. , Young ... than 5.5 pounds at birth) have an increased risk ... findings suggest that not only are [low birth weight] ...
... ... are now available in Canada from Electro Sonic. , ... Chatsworth, CA (PRWEB) July 10, 2009 -- NMB Technologies Corporation, a ... have reached a distribution agreement. Under the terms of this agreement, Electro Sonic, ...
... 10 Eli Lilly and Company (NYSE: ... 35th year of support for the Indiana Black Expo (IBE) Summer Celebration, ... presence at the IN Shape Indiana Black and Minority ... in these uncertain economic times. , , An example of this ...
... Growing in the number of those afflicted, Alzheimer,s takes ... caregivers, "Alzheimer,s Days Gone By: For Those Caring For Their ... Lueckenotte weaves a heartfelt mix of personal experience and sound ... of loved ones during the descent into dementia. , ...
... (Nasdaq: QGLY ) , ... Rosenbloom has resumed providing services to the Company,s Quigley Pharma subsidiary. ... late May, 2009. , , Ted Karkus, Chairman and interim ... Rosenbloom again serving our Pharma subsidiary and helping in the development ...
Cached Medicine News:Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 2Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 3Health News:Respiratory Issues Linger for Smallest Babies 2Health News:NMB Expands in Canada 2Health News:Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo 2Health News:Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo 3Health News:Insightful Handbook for Alzheimer's Caregivers 2Health News:Insightful Handbook for Alzheimer's Caregivers 3Health News:Dr. Richard Rosenbloom Resumes Services To The Quigley Corporation's Pharma Subsidiary 2Health News:Dr. Richard Rosenbloom Resumes Services To The Quigley Corporation's Pharma Subsidiary 3
These flexible stone retrieval devices are reusable, 3 Fr in diameter, with a working length of either 60 cm or 115 cm...
... The Brasseler USA™ MicroLine™ Small Bone ... of operation while performing under the ... powered system developed for small bone ... Drill, Sagittal Saw (Extended Length Available), ...
... Drill, with hand throttle, 30,000 ... Built-in medium bur guard included, ... bur guards are also available. ... hand throttle (#1940) for use ...
... Electric Micro Drill, without hand ... of torque. Built-in medium bur ... extra-long (#1100-006) bur guards are ... with foot throttle (#6401-000), can ...
Medicine Products: